Roivant Sciences Ltd
F:87S
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Roivant Sciences Ltd
F:87S
|
UK |
|
PlayAGS Inc
NYSE:AGS
|
US |
|
Antin Infrastructure Partners SAS
PAR:ANTIN
|
FR |
|
Nightcap PLC
LSE:NGHT
|
UK |
|
E
|
Earthworks Entertainment Inc
OTC:EWKS
|
US |
Roivant Sciences Ltd
Roivant Sciences Ltd., founded in 2014 by entrepreneur Vivek Ramaswamy, emerged as a novel entity in the pharmaceutical industry by rethinking the drug development process. At the heart of Roivant’s strategy is its unique model of deploying a family of subsidiaries, each focused on developing a specific therapeutic area, referred to as “Vants.” These subsidiaries operate semi-independently, allowing for a nimble and focused approach to drug development while sharing centralized resources like regulatory expertise and funding strategies from Roivant itself. This decentralized yet coordinated structure aims to sidestep the traditional bottlenecks of large pharmaceutical companies, accelerating the time it takes to bring drugs from development to market.
Roivant generates revenue by acquiring underdeveloped or previously shelved drug candidates from other pharmaceutical companies, then developing them through their Vants. Once these drugs have proved their potential through clinical trials, Roivant either licenses them out, partners with other companies for further development and commercialization, or sells a stake in the developed drug or entire Vant. This innovative approach allows them not only to mitigate risks associated with drug development but also to tap into a wide range of therapeutic areas, leveraging modern approaches like digital technology to optimize the drug development pipeline. Through this strategy, Roivant aims to capitalize on the inefficiencies in the pharmaceutical industry, delivering valuable medical solutions while generating substantial economic returns.
Roivant Sciences Ltd., founded in 2014 by entrepreneur Vivek Ramaswamy, emerged as a novel entity in the pharmaceutical industry by rethinking the drug development process. At the heart of Roivant’s strategy is its unique model of deploying a family of subsidiaries, each focused on developing a specific therapeutic area, referred to as “Vants.” These subsidiaries operate semi-independently, allowing for a nimble and focused approach to drug development while sharing centralized resources like regulatory expertise and funding strategies from Roivant itself. This decentralized yet coordinated structure aims to sidestep the traditional bottlenecks of large pharmaceutical companies, accelerating the time it takes to bring drugs from development to market.
Roivant generates revenue by acquiring underdeveloped or previously shelved drug candidates from other pharmaceutical companies, then developing them through their Vants. Once these drugs have proved their potential through clinical trials, Roivant either licenses them out, partners with other companies for further development and commercialization, or sells a stake in the developed drug or entire Vant. This innovative approach allows them not only to mitigate risks associated with drug development but also to tap into a wide range of therapeutic areas, leveraging modern approaches like digital technology to optimize the drug development pipeline. Through this strategy, Roivant aims to capitalize on the inefficiencies in the pharmaceutical industry, delivering valuable medical solutions while generating substantial economic returns.
Phase II Success: Roivant reported highly positive Phase II results for brepocitinib in cutaneous sarcoidosis, showing strong efficacy and an excellent safety profile.
Pipeline Momentum: The company fully enrolled key studies, including Phase IIb for 1402 in D2T RA and Phase II for mosli in PH-ILD, with multiple pivotal readouts expected in the second half of 2026.
Financial Position: Roivant ended the quarter with $4.5 billion in cash, providing significant resources to fund development and potential share buybacks.
Strong Efficacy Data: Brepocitinib achieved a placebo-adjusted 21.6-point CSAMI delta, with 100% of patients on the 45mg dose achieving at least a 10-point improvement.
Upcoming Catalysts: Numerous clinical and legal milestones are expected this year, including a Phase III start for brepocitinib in cutaneous sarcoidosis and a jury trial against Moderna starting March 9.
Market Opportunity: Management sees brepocitinib targeting large orphan indications with significant unmet need, and expects commercial launches in multiple diseases over the next few years.
